The company has received a work order worth Rs 28.29 crore from Northern Railway ... Post-inspection, the company received ...

The company has received a work order worth Rs 28.29 crore from Northern ... Post-inspection, the company received one observation in Form 483, which is procedural in nature.

At the conclusion of the inspection, the USFDA issued a Form 483 with three observations ... solar power project. The aggregate order size is 53 MW (AC), with an estimated project cost of Rs 245 crore ...

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

As Stelara biosimilars gradually make their way on to the U.S. market, Johnson & Johnson has accused one early adopter—Samsung Bioepis—of violating the settlement that paved the way for the ...

Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...

The suit seeks a preliminary injunction to bar U.S. sales of the private-label version of Samsung Bioepis' Stelara biosimilar, called Pyzchiva. Sign up here. Samsung and J&J signed a settlement ...

Godrej Properties Ltd has purchased ~10 acres of land in Yelahanka, Bengaluru to develop ~1.5 million square feet of saleable ...

Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA ...